| The company is currently seeking private and earlier stage investments to accelerate development of its cost-efficient R&D of technologies and products. The R&D team of the company takes an asset-light operation to test and realize its breakthrough ideas by signing sponsored research agreement with university labs and contract research organizations. As demonstrated in the section of Technologies, the practical feasibility of the two highly demanded breakthrough dosage forms has been proven by pre-clinic efficacy and pharmacokinetic studies involving pig and monkey models, and the company has reached the stage to take off. |
|
